このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Physical Activity in Persons With Parkinson's Disease (ActivPARK)

2026年5月13日 更新者:Erika Franzén、Karolinska Institutet

Physical Activity in Persons With Parkinson's Disease - a Longitudinal Cohort Study

This project aims to identify why some people with Parkinson's disease (PwPD) become less physically active, and which factors support or hinder activity. Understanding these factors is essential for developing person centred interventions and effective support that can be implemented in routine healthcare. A national, multicentre longitudinal cohort study will be conducted including approx 450 PwPD from five Swedish regions (including the internal pilot NCT06901869). Physical activity will be measured objectively with activity monitors, combined with clinical assessments and digital questionnaires over four years. The primary outcome is physical activity level (accelerometer measured decline), and exposure variables include physical, cognitive, disease specific, social, environmental, motivational, and personal factors. Data collection involves clinical tests, questionnaires, accelerometer data, and patient reported experiences.

This is a continuation of an internal pilot study NCT06901869. The study will enable early identification of those at risk for declining activity and guide development of person centred, evidence based interventions. Long term, it aims to integrate activity monitoring and risk factor screening into routine care to improve health and quality of life for PwPD.

調査の概要

研究の種類

観察的

入学 (推定)

450

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Compliance Office Karolinska Insitutet
  • 電話番号:+46852480000
  • メールcompliance@ki.se

研究連絡先のバックアップ

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

People with Parkinson's disease with mild to severe severity (Hoehn & Yahr 1-4) of all ages

説明

Inclusion Criteria:

  • People diagnosed with idiopathic Parkinson's disease
  • Hoehn & Yahr 1 to 4

Exclusion Criteria:

  • Hoehn & Yahr 5 (i.e. wheelchair bound or bedridden unless aided)
  • Unable to perform critical physical activity and clinical assessments

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
People with Parkinson´'s disease
No intervention

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Physical activity - low and moderate intensity
時間枠:Baseline and yearly follow-ups for 3 years
The primary outcome is changes over time in PA (i.e. low + moderate-vigorous intensity PA in time spent per day) measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Baseline and yearly follow-ups for 3 years

二次結果の測定

結果測定
メジャーの説明
時間枠
Physical activity - total vector magnitude
時間枠:Baseline and yearly follow-ups for 3 years
The secondary outcomes are change over time in total vector magnitude measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Baseline and yearly follow-ups for 3 years
Physical activity - low intensity
時間枠:Baseline and yearly follow-ups for 3 years
The secondary outcomes are change in time spent in low intensity physical activity per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Baseline and yearly follow-ups for 3 years
Physical activity - moderate high intensity
時間枠:Baseline and yearly follow-ups for 3 years
The secondary outcomes are change in time spent in moderate-vigorous physical activity per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Baseline and yearly follow-ups for 3 years
Physical activity- sedentary
時間枠:Baseline and yearly follow-ups for 3 years
The secondary outcomes are change in sedentary time per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Baseline and yearly follow-ups for 3 years
Physical activity - steps
時間枠:Baseline and yearly follow-ups for 3 years
The secondary outcomes are change in steps per day measured with accelerometers (Actigraph GT3X+, Pensacola, FL, US) during 7 days in people with Parkinson's disease everyday life.
Baseline and yearly follow-ups for 3 years

その他の成果指標

結果測定
メジャーの説明
時間枠
認知パフォーマンス
時間枠:ベースラインと3年間のフォローアップ
モントリオール認知評価(MOCA)、0-25、より高いスコア=より良い評価
ベースラインと3年間のフォローアップ
Disease severity, Parkinsons symptoms
時間枠:Baseline and 3 year follow-up

Disease severity measured with the Movement Disorders Society -Unified Parkinson's Disease Rating Scale) parts 1 to 4.

Higher scores = worse/more symptoms

Baseline and 3 year follow-up
Gait
時間枠:Baseline and 3 year follow-up
Gait speed in m/s measured with the 10 meter walking test or through gait analysis.
Baseline and 3 year follow-up
Balance performance
時間枠:Baseline and 3 year follow-up
Assessed with the Mini-BESTest. Mini-Balance Evaluation Systems Test a rating scale for dynamic balance incorporating 14 different balance and gait items that were assessed by a physical therapist on a scale from 0-2. 0-28 points with higher scores indicating better balance control
Baseline and 3 year follow-up
Anxiety and depression
時間枠:Baseline and yearly follow-ups for 3 years
Assessed with Hospital Anxiety and Depression Scale (HADS), 0-24 on the depression and anxiety part respectively. Lower score=better
Baseline and yearly follow-ups for 3 years
Motivation
時間枠:Baseline and yearly follow-ups for 3 years
Assessed with the Behavioural Regulation in Exercise Questionnaire (BREQ 4), a 28-item survey that measures exercise motivation. The questionnaire uses a 7-point Likert scale, ranging from one to seven. Maximum 196. Higher scores = higher motivation
Baseline and yearly follow-ups for 3 years
Self-efficacy
時間枠:Baseline and yearly follow-ups for 3 years
Assessed with the Self-efficacy and motivation for exercise/physical activity (ESES). 10 questions rated on a 4 point Likert scale. Maximun 40 points, higher scores= better self-efficacy
Baseline and yearly follow-ups for 3 years
Physical activity history and preferences,
時間枠:Baseline
Self-made questions on physical activity history and preferences
Baseline
Self assessed cognitive function
時間枠:Baseline and yearly follow-ups for 3 years
Assessed with Executive function questionnaire (DEX), 20 items scored 1 to 4, max 80, more scores= worse
Baseline and yearly follow-ups for 3 years
Non-Motor Symptoms
時間枠:Baseline and yearly follow-ups for 3 years
Non-Motor Symptoms Questionnaire (NMSQ), 30 questions with yes/no answer. More yes answers = more non-motor symptoms
Baseline and yearly follow-ups for 3 years
Walking ability- self rated
時間枠:Baseline and yearly follow-ups for 3 years
WALK-12G questionnaire, 0 and 42 points, with higher scores reflecting greater perceived walking difficulties (higher=worse)
Baseline and yearly follow-ups for 3 years
Freezing of gait - self-assessed
時間枠:Baseline and 3 year follow-up
Freezing of gait questionnaire (FOGQsa), 6 questions/items, scored 1 to 5 (higher=worse)
Baseline and 3 year follow-up
Balance confidence
時間枠:Baseline and yearly follow-ups for 3 years
Activities specific balance confidence (ABC scale), 16 items which is scored 1 to 10 and then divided by 16. 0-100%, higher % = better
Baseline and yearly follow-ups for 3 years
Fatigue
時間枠:Baseline and yearly follow-ups for 3 years
Parkinson's Fatigue Scale (PFS-16), 16 items scored 1 to 5 from strongly disagree to strongly agree . more points/score= worse.
Baseline and yearly follow-ups for 3 years
Disability
時間枠:Baseline and 3 year follow-up
World health organization (WHO) disability assessment schedule (Whodas 2.0), 12 self-assessed questions (12 to 60) more points=worse
Baseline and 3 year follow-up
Sleep
時間枠:Baseline and 3 year follow-up
Scales for Outcomes in Parkinson's disease - Sleep (SCOPA-SLEEP), 4 parts, A-2 questions, B-5 questions , C-1 question and D- 6 questions. Higher= worse
Baseline and 3 year follow-up
Self-rated pain
時間枠:Baseline and yearly follow-ups for 3 years
Assessed with visual analog scale, VAS from 0 to 100
Baseline and yearly follow-ups for 3 years
Health related quality of life
時間枠:Baseline and yearly follow-ups for 3 years
Parkinson's Disease Questionnaire (PDQ39). The Parkinson's Disease Questionnaire (PDQ-39) assesses how often people with Parkinson's experience difficulties across 8 dimensions of daily living (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communications and bodily discomfort). The sum score is as a percentage score ranging between 0 and 100. Higher is better
Baseline and yearly follow-ups for 3 years
Wellbeing
時間枠:Baseline and yearly follow-ups for 3 years
The WHO- Five Well-Being Index (WHO-5), 5 questions ranging from 0 to 5, 0-25, higher=better
Baseline and yearly follow-ups for 3 years
Nutrition
時間枠:Baseline and 3 year follow-up
Mini Nutritional Assessment, max 14. higher = better
Baseline and 3 year follow-up
Socioeconomic status
時間枠:Baseline
Education and income level.
Baseline

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月15日

一次修了 (推定)

2030年12月31日

研究の完了 (推定)

2031年1月30日

試験登録日

最初に提出

2026年5月7日

QC基準を満たした最初の提出物

2026年5月7日

最初の投稿 (実際)

2026年5月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月15日

QC基準を満たした最後の更新が送信されました

2026年5月13日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 4-438/2024
  • 2024-07526-01 (その他の識別子:Swedish Ethical Review Authority)
  • 06901869 (その他の識別子:Clinical Trials registration -pilot study)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient, provided that the recipient has an approved ethics application.

IPD 共有時間枠

We plan to share this when applicable on OSF or similar

IPD 共有アクセス基準

The datasets generated during and/or analysed during the current study are not publicly available due to Swedish and EU personal data legislation but are available from the principal investigator on reasonable request. Any sharing of data will be regulated via a data transfer and user agreement with the recipient.

IPD 共有サポート情報タイプ

  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する